Physician profile
Azhar Amil
NPI 1568413284
$3,991.74
in general payments reported to CMS, 2019-2025
31 companies · $802 in 2025
The $802 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,191 · 2020: $472 · 2021: $252 · 2022: $600 · 2023: $91.69 · 2024: $584 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126 · Travel and Lodging: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.47 |
| Travel and Lodging | $350.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $619.83 | 2025 | Barostim Neo System |
| Acist Medical Systems, INC. | $608.70 | 2019 | |
| Abiomed | $445.33 | 2022-2024 | Impella |
| Medtronic, INC. | $199.80 | 2021-2022 | |
| Pfizer INC. | $191.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $190.96 | 2019-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $172.22 | 2019-2020 | |
| Edwards Lifesciences Corporation | $167.48 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $153.46 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $130.19 | 2020-2025 | |
| Heartflow, INC. | $118.98 | 2019 | |
| Cardiovascular Systems INC. | $118.00 | 2020-2022 | |
| Boston Scientific Corporation | $112.42 | 2019-2021 | |
| Medtronic Vascular, INC. | $94.96 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.00 | 2023-2025 | Lifevest |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $80.78 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.40 | 2020-2022 | |
| Lexicon Pharmaceuticals, INC. | $60.00 | 2024 | Inpefa |
| Philips North America LLC | $58.29 | 2024 | (Ck4) Mcot |
| Kiniksa Pharmaceuticals International, Plc | $51.88 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $49.17 | 2021-2022 | |
| Novo Nordisk INC | $48.90 | 2022-2025 | Wegovy, Ozempic |
| Kestra Medical Technology Services, INC. | $34.38 | 2023 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $28.36 | 2024 | Onpattro |
| Atricure, INC. | $21.68 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.46 | 2021 | |
| Gilead Sciences, INC. | $17.48 | 2019 | |
| Irhythm Technologies, INC. | $14.89 | 2024 | Zio Monitor, Zio Xt Patch |
| Inari Medical, INC. | $13.44 | 2019 | |
| Penumbra, INC. | $11.12 | 2021 | |
| Althera Pharmaceuticals LLC | $5.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azhar Amil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.